ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Gene Therapy for Age-related Macular Degeneration Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-2S13639
Home | Market Reports | Health| Vision Care
Global Gene Therapy for Age related Macular Degeneration Market Research Report 2023
BUY CHAPTERS

Global Gene Therapy for Age-related Macular Degeneration Market Research Report 2025

Code: QYRE-Auto-2S13639
Report
September 2025
Pages:65
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
RetroSense Therapeutics
REGENXBIO
AGTC

Gene Therapy for Age-related Macular Degeneration Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Gene Therapy for Age-related Macular Degeneration Market

Gene Therapy for Age-related Macular Degeneration Market

The global market for Gene Therapy for Age-related Macular Degeneration was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Age-related Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Age-related Macular Degeneration.
The Gene Therapy for Age-related Macular Degeneration market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gene Therapy for Age-related Macular Degeneration market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Therapy for Age-related Macular Degeneration companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Gene Therapy for Age-related Macular Degeneration Market Report

Report Metric Details
Report Name Gene Therapy for Age-related Macular Degeneration Market
CAGR 5%
Segment by Type
  • Subretinal
  • Intravitreal
Segment by Application
  • Monotherapy
  • Combination Therapy
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company RetroSense Therapeutics, REGENXBIO, AGTC
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Gene Therapy for Age-related Macular Degeneration company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Gene Therapy for Age-related Macular Degeneration Market report?

Ans: The main players in the Gene Therapy for Age-related Macular Degeneration Market are RetroSense Therapeutics, REGENXBIO, AGTC

What are the Application segmentation covered in the Gene Therapy for Age-related Macular Degeneration Market report?

Ans: The Applications covered in the Gene Therapy for Age-related Macular Degeneration Market report are Monotherapy, Combination Therapy

What are the Type segmentation covered in the Gene Therapy for Age-related Macular Degeneration Market report?

Ans: The Types covered in the Gene Therapy for Age-related Macular Degeneration Market report are Subretinal, Intravitreal

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Subretinal
1.2.3 Intravitreal
1.3 Market by Application
1.3.1 Global Gene Therapy for Age-related Macular Degeneration Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Monotherapy
1.3.3 Combination Therapy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy for Age-related Macular Degeneration Market Perspective (2020-2031)
2.2 Global Gene Therapy for Age-related Macular Degeneration Growth Trends by Region
2.2.1 Global Gene Therapy for Age-related Macular Degeneration Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Gene Therapy for Age-related Macular Degeneration Historic Market Size by Region (2020-2025)
2.2.3 Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Region (2026-2031)
2.3 Gene Therapy for Age-related Macular Degeneration Market Dynamics
2.3.1 Gene Therapy for Age-related Macular Degeneration Industry Trends
2.3.2 Gene Therapy for Age-related Macular Degeneration Market Drivers
2.3.3 Gene Therapy for Age-related Macular Degeneration Market Challenges
2.3.4 Gene Therapy for Age-related Macular Degeneration Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue
3.1.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue (2020-2025)
3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Players (2020-2025)
3.2 Global Gene Therapy for Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Gene Therapy for Age-related Macular Degeneration Revenue
3.4 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio
3.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Age-related Macular Degeneration Revenue in 2024
3.5 Global Key Players of Gene Therapy for Age-related Macular Degeneration Head office and Area Served
3.6 Global Key Players of Gene Therapy for Age-related Macular Degeneration, Product and Application
3.7 Global Key Players of Gene Therapy for Age-related Macular Degeneration, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy for Age-related Macular Degeneration Breakdown Data by Type
4.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Type (2020-2025)
4.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2026-2031)
5 Gene Therapy for Age-related Macular Degeneration Breakdown Data by Application
5.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Application (2020-2025)
5.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Gene Therapy for Age-related Macular Degeneration Market Size (2020-2031)
6.2 North America Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2020-2025)
6.4 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size (2020-2031)
7.2 Europe Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2020-2025)
7.4 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size (2020-2031)
8.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2020-2025)
8.4 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy for Age-related Macular Degeneration Market Size (2020-2031)
9.2 Latin America Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2020-2025)
9.4 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size (2020-2031)
10.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2020-2025)
10.4 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 RetroSense Therapeutics
11.1.1 RetroSense Therapeutics Company Details
11.1.2 RetroSense Therapeutics Business Overview
11.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Introduction
11.1.4 RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2020-2025)
11.1.5 RetroSense Therapeutics Recent Development
11.2 REGENXBIO
11.2.1 REGENXBIO Company Details
11.2.2 REGENXBIO Business Overview
11.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Introduction
11.2.4 REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2020-2025)
11.2.5 REGENXBIO Recent Development
11.3 AGTC
11.3.1 AGTC Company Details
11.3.2 AGTC Business Overview
11.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Introduction
11.3.4 AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2020-2025)
11.3.5 AGTC Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
RetroSense Therapeutics
REGENXBIO
AGTC
List of Tables
 Table 1. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Subretinal
 Table 3. Key Players of Intravitreal
 Table 4. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Gene Therapy for Age-related Macular Degeneration Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Gene Therapy for Age-related Macular Degeneration Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region (2020-2025)
 Table 8. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region (2026-2031)
 Table 10. Gene Therapy for Age-related Macular Degeneration Market Trends
 Table 11. Gene Therapy for Age-related Macular Degeneration Market Drivers
 Table 12. Gene Therapy for Age-related Macular Degeneration Market Challenges
 Table 13. Gene Therapy for Age-related Macular Degeneration Market Restraints
 Table 14. Global Gene Therapy for Age-related Macular Degeneration Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players (2020-2025)
 Table 16. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2024)
 Table 17. Ranking of Global Top Gene Therapy for Age-related Macular Degeneration Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Gene Therapy for Age-related Macular Degeneration, Headquarters and Area Served
 Table 20. Global Key Players of Gene Therapy for Age-related Macular Degeneration, Product and Application
 Table 21. Global Key Players of Gene Therapy for Age-related Macular Degeneration, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Gene Therapy for Age-related Macular Degeneration Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2020-2025)
 Table 25. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2026-2031)
 Table 27. Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2020-2025)
 Table 29. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2026-2031)
 Table 31. North America Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2026-2031) & (US$ Million)
 Table 46. RetroSense Therapeutics Company Details
 Table 47. RetroSense Therapeutics Business Overview
 Table 48. RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Product
 Table 49. RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2020-2025) & (US$ Million)
 Table 50. RetroSense Therapeutics Recent Development
 Table 51. REGENXBIO Company Details
 Table 52. REGENXBIO Business Overview
 Table 53. REGENXBIO Gene Therapy for Age-related Macular Degeneration Product
 Table 54. REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2020-2025) & (US$ Million)
 Table 55. REGENXBIO Recent Development
 Table 56. AGTC Company Details
 Table 57. AGTC Business Overview
 Table 58. AGTC Gene Therapy for Age-related Macular Degeneration Product
 Table 59. AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2020-2025) & (US$ Million)
 Table 60. AGTC Recent Development
 Table 61. Research Programs/Design for This Report
 Table 62. Key Data Information from Secondary Sources
 Table 63. Key Data Information from Primary Sources
 Table 64. Authors List of This Report


List of Figures
 Figure 1. Gene Therapy for Age-related Macular Degeneration Picture
 Figure 2. Global Gene Therapy for Age-related Macular Degeneration Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Gene Therapy for Age-related Macular Degeneration Market Share by Type: 2024 VS 2031
 Figure 4. Subretinal Features
 Figure 5. Intravitreal Features
 Figure 6. Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Gene Therapy for Age-related Macular Degeneration Market Share by Application: 2024 VS 2031
 Figure 8. Monotherapy Case Studies
 Figure 9. Combination Therapy Case Studies
 Figure 10. Gene Therapy for Age-related Macular Degeneration Report Years Considered
 Figure 11. Global Gene Therapy for Age-related Macular Degeneration Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 12. Global Gene Therapy for Age-related Macular Degeneration Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region: 2024 VS 2031
 Figure 14. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players in 2024
 Figure 15. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2024)
 Figure 16. The Top 10 and 5 Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue in 2024
 Figure 17. North America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 18. North America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2020-2031)
 Figure 19. United States Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. Canada Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Europe Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Gene Therapy for Age-related Macular Degeneration Market Share by Country (2020-2031)
 Figure 23. Germany Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. France Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. U.K. Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Italy Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Russia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Nordic Countries Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Share by Region (2020-2031)
 Figure 31. China Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Japan Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. South Korea Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. India Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Australia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Latin America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2020-2031)
 Figure 39. Mexico Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Brazil Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Share by Country (2020-2031)
 Figure 43. Turkey Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Saudi Arabia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. UAE Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. RetroSense Therapeutics Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2020-2025)
 Figure 47. REGENXBIO Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2020-2025)
 Figure 48. AGTC Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2020-2025)
 Figure 49. Bottom-up and Top-down Approaches for This Report
 Figure 50. Data Triangulation
 Figure 51. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Single-Port Vitrectomy Cutter Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13L12609
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Eye Ultrasound Biomicroscope Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32B20021
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Plano-Convex Laser Lenses Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-38C19846
Tue Dec 02 00:00:00 UTC 2025

Add to Cart

Global Heated Eye Masks Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-2H20253
Thu Nov 27 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions